Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (47)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smyth, J. F.
Right arrow Articles by Tedeschi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, J. F.
Right arrow Articles by Tedeschi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:569-573, 1997
© 1997 European Society for Medical Oncology

research-article

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial

J. F. Smyth1,, A. Bowman1, T. Perren2, P. Wilkinson3, R. J. Prescott4, K. J. Quinn5 and M. Tedeschi6

1ICRF Medical Oncology Unit, Western General Hospital Edinburgh, UK
2ICRF Cancer Medicine Research Unit, St. James's University Hospital Leeds, UK
3Christie Hospital Manchester, UK
4Medical Statistics Unit, University of Edinburgh UK
5Boehringer Mannheim UK
6Boehringer Mannheim Italy

Correspondence to: Prof. J F Smyth ICRF Medical Oncology Unit Western General Hospital Crewe Road Edinburgh EH4 2XU Scotland

BACKGROUND: Early clinical trials have suggested that glutathione (GSH) offers protection from the toxic effects of cisplatin.

PATIENTS AND METHODS: One hundred fifty-one patients with ovarian cancer (stage I–IV) were evaluated in a clinical trial of cisplatin (CDDP) ± glutathione (GSH). The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity.

RESULTS: When considering the proportion of patients receiving six courses of CDDP at any dose, GSH produced a significant advantage over control - 58% versus 39%, (P = 0.04). For these patients there was a significant difference between the reduction in creatinine clearance for GSH treated patients compared with control - 74% versus 62% (P = 0.006). Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating. As an indication of overall activity, these patients were statistically significantly more able to undertake housekeeping and shopping. Clinically assessed response to treatment demonstrated a trend towards a better outcome in the GSH group (73% versus 62%) but this was not statistically significant (P = 0.25).

CONCLUSIONS: The results demonstrate that adding GSH to CDDP allows more cycles of CDDP treatment to be administered because less toxicity is observed and the patient's quality of life is improved.

cisplatin, glutathione, platinum, toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
B. D. Lawenda, K. M. Kelly, E. J. Ladas, S. M. Sagar, A. Vickers, and J. B. Blumberg
Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
J Natl Cancer Inst, June 4, 2008; 100(11): 773 - 783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
R. W. Moss
Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?
Integr Cancer Ther, March 1, 2006; 5(1): 63 - 82.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
W. A. Weiger, M. Smith, H. Boon, M. A. Richardson, T. J. Kaptchuk, and D. M. Eisenberg
Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer
Ann Intern Med, December 3, 2002; 137(11): 889 - 903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Cascinu, V. Catalano, L. Cordella, R. Labianca, P. Giordani, A. M. Baldelli, G. D. Beretta, E. Ubiali, and G. Catalano
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
J. Clin. Oncol., August 15, 2002; 20(16): 3478 - 3483.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.